Patentability, Biosimilars Top Life Sciences Issues for 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.

January 13, 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

Related Publications

March 13, 2023
February 22, 2023
A World Without Noncompetes: Protecting Confidential Information and Trade Secrets
Chris Larus, David Prange, Rajin Olson - The National Law Journal
February 7, 2023
When Monkey Business Slips Into Trademark Infringement
David Martinez and Zac Cohen - Los Angeles & San Francisco Daily Journal
Fourth Quarter
Generically Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Bernard Pound
Fourth Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
Back to Top